Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 91

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 91
---
 financing (the “2024 Private Placement”), with certain institutional and accredited investors (the “Purchasers”). The Purchasers included (i) Timothy A. Springer, Ph.D.; (ii) TAS, an affiliate of Dr. Springer, and (iii) Dr. Chafen Lu, Dr. Springer’s wife. We granted customary registration rights to investors in connection with the 2024 Private Placement. For further description of the 2024 Private Placement, see Note 11 to our consolidated audited financial statements included in our 2024 Annual Report. The below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.

| Name                                                      |     | Shares of Series B Preferred Stock purchased |           |     | Total aggregate purchase price 
 (in thousands)                 |        |
|:----------------------------------------------------------|:----|:---------------------------------------------|----------:|:----|:-------------------------------|-------:|
| Timothy A. Springer, Ph.D.                                |     |                                              | 1,636,832 |     | $                              | 32,737 |
| TAS Partners LLC, affiliate of Timothy A. Springer, Ph.D. |     |                                              |   721,361 |     | $                              | 14,427 |
| Chafen Lu, Ph.D., wife of Timothy A. Springer, Ph.D.      |     |                                              |     1,307 |     | $                              |     26 |

#### Indemnification Agreements
We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital

<div align='center'>54</div>

funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by a director or an executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of such person’s services as a director or executive officer.

#### Stockholders’ Proposals
Requirements for Stockholder Proposals or Nominations to be Brought Before the Annual Meeting. Stockholders intending to present a proposal at the 2026 Annual Meeting of Stockholders, but not to include the proposal in our proxy statement, or to nominate a person for election as a director, must comply with the requirements set forth in our Bylaws